posted on 2016-02-19, 01:43authored byJames E. Dowling, Marat Alimzhanov, Larry Bao, Michael H. Block, Claudio Chuaqui, Emma L. Cooke, Christopher R. Denz, Alex Hird, Shan Huang, Nicholas A. Larsen, Bo Peng, Timothy W. Pontz, Caroline Rivard-Costa, Jamal Carlos Saeh, Kumar Thakur, Qing Ye, Tao Zhang, Paul D. Lyne
In
this letter, we describe the design, synthesis, and structure–activity
relationship of 5-anilinopyrazolo[1,5-a]pyrimidine inhibitors of CK2
kinase. Property-based optimization of early leads using the 7-oxetan-3-yl
amino group led to a series of matched molecular pairs with lower
lipophilicity, decreased affinity for human plasma proteins, and reduced
binding to the hERG ion channel. Agents in this study were shown to
modulate pAKTS129, a direct substrate of CK2, in vitro
and in vivo, and exhibited tumor growth inhibition when administered
orally in a murine DLD-1 xenograft.